Mitoxantrone Hydrochloride Liposome, intravenous injection (IV)

DRUG3 trials

Sponsors

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Conditions

Advanced Solid TumorMetastatic Head and Neck CancerPlatinum-resistant Ovarian CancerRecurrent Head and Neck Cancer

Phase 1

A Study of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Relapsed Ovarian Cancer

TerminatedNCT04718376

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Platinum-resistant Ovarian Cancer

Start: 2021-01-12End: 2023-05-22Updated: 2024-03-07

A Study of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Advanced Solid Tumor

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Advanced Solid Tumor

Start: 2021-01-13End: 2024-04-13Target: 90Updated: 2021-11-01

A Study of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Recurrent/Metastatic Head and Neck Cancers

CompletedNCT04902027

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Metastatic Head and Neck Cancer, Recurrent Head and Neck Cancer

Start: 2021-07-01End: 2023-10-23Updated: 2024-03-07

Related Papers

Mitoxantrone hydrochloride liposome injection in the treatment of recurrent/metastatic head and neck cancers: A multicenter, open-label, single-arm, phase Ⅰb study.

Journal of Clinical Oncology2022-06-011 citations

Safety and efficacy of mitoxantrone hydrochloride liposome in patients with platinum-refractory or platinum-resistant ovarian cancer: A prospective, multicenter, open-label, single-arm, phase Ib clinical trial.

Journal of Clinical Oncology2022-06-011 citations